7 active not recruiting, 6 recruiting, 2 terminated, 1 approved for marketing. 10 Phase 2, 8 Phase 1, 3 Not applicable, 2 Phase 3, 1 Phase 4.
Follow Diffuse Large B-Cell Lymphoma, Not Otherwise Specified: new trials by email Literature Review of Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trials Research Report on Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 15 | 2026-10-09 | 2026-08-13 |
| Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 2 | Recruiting | University of Washington | 18 | 2025-12-07 | 2026-10-21 |
| ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL Phased Variant Enrichment and Detection Sequencing (PhasED-seq), Standard of Care Treatment, De-escalated Treatment - Lymphoma, Lymphoma, B-Cell | Not applicable | Recruiting | Hua-Jay J Cherng, MD | 40 | 2024-12-11 | 2026-01-23 |
| A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma Fludarabine, Cyclophosphamide, WZTL-002 CAR T-cells - Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | Malaghan Institute of Medical Research | 60 | 2024-07-12 | 2026-08-07 |
| Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Lenalidomide - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-05-20 | 2026-07-09 |
| P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies P-CD19CD20-ALLO1, Rimiducid - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma | Phase 1 | Active not recruiting | Poseida Therapeutics, Inc. | 120 | 2024-04-16 | 2026-05-07 |
| Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy Biopsy, Biospecimen Collection, Computed Tomography - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma | Phase 2 | Recruiting | Academic and Community Cancer Research United | 120 | 2024-01-31 | 2024-09-26 |
| A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies IDP-121 - Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Recruiting | IDP Discovery Pharma S.L. | 37 | 2023-06-05 | 2025-05-01 |
| Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma selinexor - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 4 | Unknown | Chongqing University Cancer Hospital | 32 | 2023-02-28 | 2023-03-28 |
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 422 | 2021-05-20 | 2026-10-01 |
| Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma Acalabrutinib, Axicabtagene Ciloleucel - B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 23 | 2020-12-02 | 2026-06-25 |
| Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma Polatuzumab Vedotin, Rituximab, Prednisone - Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 56 | 2020-10-27 | 2026-10-02 |
| Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma | Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 23 | 2020-03-04 | 2026-02-27 |
| Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 363 | 2019-10-22 | 2026-10-22 |
| Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients 89Zr-atezolizumab PET scans - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Not applicable | Withdrawn | University Medical Center Groningen | 2019-05-22 | 2023-05-15 | |
| Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone - Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 1 | Completed | Northwestern University | 12 | 2019-03-13 | 2025-06-18 |
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Nivolumab, Varlilumab - ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2018-12-21 | 2026-05-12 |
| Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma Molecular Nanotechnology - Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | Not applicable | Active not recruiting | Ohio State University Comprehensive Cancer Center | 73 | 2018-09-26 | 2026-08-06 |
| JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Cyclophosphamide, Durvalumab - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 30 | 2016-11-15 | 2022-08-24 |
| Expanded Access Program for Epcoritamab Epcoritamab - Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Approved for marketing | Genmab | 2023-05-25 |
Lymphoma, Large B-Cell, Diffuse (20) · Lymphoma, B-Cell (4) · Lymphoma, Non-Hodgkin (3) · Burkitt Lymphoma (2) · Lymphoma (2) · Lymphoma, Primary Effusion (2) · Plasmablastic Lymphoma (2) · Dendritic Cell Sarcoma, Interdigitating (1) · Disease Progression (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphomatoid Granulomatosis (1) · Multiple Myeloma (1) · Neoplasm, Residual (1)
Hemic and Lymphatic Diseases (20) · Immune System Diseases (20) · Immunoproliferative Disorders (20) · Lymphatic Diseases (20) · Lymphoproliferative Disorders (20) · Neoplasms (20) · Neoplasms by Histologic Type (20) · Lymphoma (18) · Lymphoma, Non-Hodgkin (17) · Lymphoma, B-Cell (16) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · DNA Virus Infections (2) · Disease Attributes (2) · Epstein-Barr Virus Infections (2)
Cyclophosphamide (9) · Doxorubicin (6) · Magnetic Resonance Spectroscopy (6) · Prednisone (6) · Rituximab (6) · Specimen Handling (6) · deltacortene (6) · CT-P10 (5) · prednylidene (5) · Biopsy (4) · Vincristine (4) · Etoposide (3) · fludarabine (3) · Disulfides (2) · Immunoglobulin G (2)
National Cancer Institute (NCI) (5) · University of Washington (3) · Academic and Community Cancer Research United (1) · Chongqing University Cancer Hospital (1) · Fred Hutchinson Cancer Center (1) · Genmab (1) · Hua-Jay J Cherng, MD (1) · IDP Discovery Pharma S.L. (1) · Jonsson Comprehensive Cancer Center (1) · Malaghan Institute of Medical Research (1) · Northwestern University (1) · Ohio State University Comprehensive Cancer Center (1) · Poseida Therapeutics, Inc. (1) · University Medical Center Groningen (1)
United States (14) · China (1) · Netherlands (1) · New Zealand (1) · Spain (1)
Ajay Gopal (1) · Beth Christian, MD (1) · Elizabeth A Brem (1) · Enrique Ocio San Miguel, MD, PhD (1) · Grzegorz S Nowakowski (1) · Hua-Jay J Cherng, MD (1) · Jeremy S Abramson (1) · John M Timmerman, MD (1) · Jordan Gauthier (1) · Joseph M Tuscano (1) · Marcel Nijland, MD (1) · Mengyang Di, MD, PhD (1) · Philip George, MBChB (1) · Reem Karmali (1) · Robert Weinkove, PhD (1)
PMID 16648042, PMID 19219604, PMID 20660832, PMID 23615461, PMID 23753028, PMID 25934708, PMID 29155058, PMID 29437609, PMID 29610030, PMID 29654631, PMID 30881137, PMID 32487143, PMID 32589977, PMID 33148342, PMID 33202794, PMID 33764240, PMID 34515338, PMID 34634256, PMID 34686472, PMID 36521030, PMID 37903325, PMID 40802906, PMID 42660130, PMID 7477169
2017 (1), P30CA015083 (1), P30CA015704 (1), P30CA060553 (1), R01CA136551 (1), R03CA286676 (1), U10CA180821 (1), U10CA180888 (1), UM1CA121947 (1), UM1CA186686 (1), UM1CA186709 (1), UM1CA186717 (1)